Idexx Laboratories (IDXX) - FREE Research Report

Szostak M Anne who is Director at Idexx Laboratories bought 1,000 shares at $108.24 on Nov. 6, 2013. Following this transaction, the Director owned 3,000 shares meaning that the stake was reduced by 50% with the 1,000 share transaction.

The shares most recently traded at $108.91, up $0.67, or 0.62% since the insider transaction. Historical insider transactions for Idexx Laboratories go as follows:

  • 4-Week # shares sold: 2,500
  • 12-Week # shares sold: 3,513
  • 24-Week # shares sold: 3,513

The average volume for Idexx Laboratories has been 257,300 shares per day over the past 30 days. Idexx Laboratories has a market cap of $5.6 billion and is part of the health care sector and drugs industry. Shares are up 17.11% year to date as of the close of trading on Wednesday.

IDEXX Laboratories, Inc. develops, manufactures, and distributes various products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets worldwide. The company has a P/E ratio of 31.7. Currently there are 5 analysts that rate Idexx Laboratories a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on IDXX - FREE

TheStreet Quant Ratings rates Idexx Laboratories as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, increase in net income, notable return on equity and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Idexx Laboratories Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Regeneron Pharmaceuticals Ready to Make All-Time Highs

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst

Biotech movers: CEL-SCI Leaps After FDA Lets Cancer Study Move Forward

If It's Not Earnings News, It's Amazon Competition: Jim Cramer's Best Blog

Electronic Arts, Activision Blizzard and Take-Two Interactive: 'Mad Money' Lightning Round